Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer
Authors not listed
National Cancer Institute, Naples · 2000
Abstract
The purpose of this study is to describe the activity and toxicity of gemcitabine combined with four different drugs (carboplatin or cisplatin or etoposide or vinorelbine) as first line treatment of elderly patients with extensive small cell lung cancer.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-03 MST
Cite this
APA
Anonymous. (2000). Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer. <em>National Cancer Institute, Naples</em>. https://clinicaltrials.gov/study/NCT00401609
Vancouver
Anonymous. Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer. National Cancer Institute, Naples. 2000.
BibTeX
@misc{anon2000Evalua,
title = {Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer},
author = {Anonymous},
journal = {National Cancer Institute, Naples},
year = {2000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
National Cancer Institute, Naples 2002
Open access · US-GOV
Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients
National Cancer Institute, Naples 2011
Open access · US-GOV
Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.
Sumitomo Pharma Co., Ltd. 2006
Open access · US-GOV
Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer
Groupe Francais De Pneumo-Cancerologie 2006
Open access · US-GOV
A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.
SCRI Development Innovations, LLC 2007
Open access · US-GOV
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hellenic Oncology Research Group 2010
Open access · US-GOV